Bormioli Pharma, known for partnering with customers to provide total packaging solutions for injectable drugs, has announced strong business growth in North America in 2022. Growth in North America was matched by strong sales gains in the company’s markets, reflecting Bormioli’s multi-million dollar investments in its ability to provide total packaging solutions for injectable drugs.
In the year Founded in 1825 as Bormioli Rocco, manufacturer of glass containers, Bormioli Pharma has a long history in the packaging industry. Now, as a strategic partner of many leading pharmaceutical manufacturers, the company serves the pharmaceutical and biopharmaceutical markets with complete packaging solutions including glass and plastic bottles, plastic and aluminum closures and accessories.
The US glass bottle market is experiencing ongoing supply issues for injectable glass packaging due to the adverse effects of the Covid-19 pandemic and supply chain disruptions. Bormioli is committed to providing a comprehensive solution with ever-expanding capabilities in the areas of high-value glass bottles, rubber stoppers and aluminum seals. In particular, the company has invested in strengthening the capacity of tubular glass bottles with advanced machinery, upgrading the molded glass platform and expanding the clean room capacity for the production of rubber stoppers. These developments are supported by recent acquisitions that enable Bormioli to reliably and efficiently manufacture rubber and aluminum closures as well as tubular glass bottles.
For almost 200 years, we have been leading the field of molded glass manufacturing and now we are extending those skills to tubular glass bottles.
Our proud history is matched by our current passion for innovation in providing innovative, comprehensive packaging solutions to pharmaceutical manufacturers. As a single supplier of all injection drug kit components, we are able to provide cost-effective and flexible solutions based on customer needs and are pursuing an ambitious agenda to significantly enhance the sustainability of all our operations. Our multilateral commitments are driven by two main factors: supply chain issues that remind us of the inescapable risks of a shortage of glass containers for injectable drugs and ongoing climate change.
Andrea Lodetti, CEO, Bormioli Pharma.
Bormioli Pharma products help ensure maximum drug stability by protecting drugs from degradation, prolonging drug stability, and providing accurate dosing, thereby contributing to the health of individuals receiving treatment.
Waiting for the next 200Th Bormioli Pharma established a program with the ambitious goal of “50-by-5” to achieve 50% sustainable raw materials in its pharmaceutical packaging products by 2025. “50-in-5” is a project that affects the entire manufacturing footprint. To achieve this ambitious goal, the company is strengthening and expanding its industrial platform, with investments estimated at more than 50 million euros to date, with similar investments to be made in the next three years. Strategies include increasing the percentage of recycled materials in the production process and adopting carbon capture and other green materials for container closures and seals.
To learn more about this initiative and Bormioli’s comprehensive packaging solutions, please see Bormioli executives at DCAT Week 2023 or contact the US sales representative on the website at firstname.lastname@example.org.